ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC)

CAPS Rating: 3 out of 5

Results 1 - 9 of 9

Recs

0
Member Avatar dividendum (< 20) Submitted: 3/14/2014 12:27:14 PM : Outperform Start Price: $1.26 IMUC Score: -51.77

It is going to hit 6 dollars by the end of 2014.
Biotechnology is on the rise.

Recs

0
Member Avatar investor17390 (< 20) Submitted: 10/21/2013 12:58:57 AM : Outperform Start Price: $2.96 IMUC Score: -89.28

according to the company, we can expect results from the ict-107 phase II trail.

Recs

0
Member Avatar K28hill (< 20) Submitted: 9/11/2013 12:48:25 PM : Outperform Start Price: $2.86 IMUC Score: -92.04

several good products progressing in the pipeline.

Recs

0
Member Avatar awosha1 (72.24) Submitted: 5/16/2013 6:36:59 AM : Outperform Start Price: $2.47 IMUC Score: -90.63

Strong pipeline. low requirement for approval. Just needs to "same or better" then current treatments for GBMF (Brain cancer). and current treatment is frankly poor. Chance of no approval is almost zero.

Recs

0
Member Avatar LouisAIrl (< 20) Submitted: 9/14/2012 8:24:02 AM : Outperform Start Price: $2.80 IMUC Score: -108.64

Research in pipeline

Recs

0
Member Avatar ayuddha (30.22) Submitted: 7/15/2012 5:20:25 PM : Outperform Start Price: $3.45 IMUC Score: -124.87

It was picked by www.hechtsoft.de Trade Alerts.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 7:42:42 PM : Outperform Start Price: $3.62 IMUC Score: -124.26

Has a cancer vaccine that appears very promising.

Recs

0
Member Avatar BuffettJunior1 (97.62) Submitted: 9/27/2011 2:06:30 PM : Underperform Start Price: $1.50 IMUC Score: +118.73

Too easy!

Recs

0
Member Avatar alomba48 (32.51) Submitted: 6/23/2011 1:13:59 PM : Outperform Start Price: $2.26 IMUC Score: -123.83

Definitely speculative, but I figure the technology is interesting and some bright phase one clinical trial results are enough for me to take the risk

Results 1 - 9 of 9

Featured Broker Partners


Advertisement